Cite
HARVARD Citation
Thaçi, D. et al. (2017). Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. Journal of the European Academy of Dermatology and Venereology. pp. 498-506. [Online].